Dupixent vs Jakafi
Side-by-side drug price comparison from Medicare Part D data
Verdict
Dupixent costs 75% less per claim than Jakafi ($2819.00 vs $11432.00). Neither drug has a generic alternative available. Total Medicare spending: Dupixent at $4.4B vs Jakafi at $2.7B.
| Metric | Dupixent | Jakafi |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $2,819* | $11,432 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.4B | $2.7B |
| Total Claims | 1,560,000 | 236,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 35.2% | 11.2%* |
| Generic Available | No | No |
| Condition | Autoimmune Diseases | Cancer |
| Total Beneficiaries | 245,000 | 22,000 |
Dupixent costs 75% less per claim than Jakafi ($2819.00 vs $11432.00). Neither drug has a generic alternative available. Total Medicare spending: Dupixent at $4.4B vs Jakafi at $2.7B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Dupixent and Jakafi. What follows is the interpretation — which specific axes carry the most weight for Dupixent versus Jakafi, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.